ArticleCurrent pharmaceutical biotechnology2011
Simvastatin is protective during Staphylococcus aureus pneumonia.
Article in Current pharmaceutical biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Statins, Allies against Antibiotic Resistance?Current medicinal chemistry · 2025Review
- Triglyceride levels are associated with 30-day mortality in intensive care patients: a retrospective analysis in the MIMIC-IV database.European journal of medical research · 2024Article
- Statin Use and Reduced Risk of Pneumonia in Patients with Melioidosis: A Lung-Specific Statin Association.Annals of the American Thoracic Society · 2024Article
- Innovations in Evaluating Statin Benefit and Efficacy inInternational journal of molecular sciences · 2022Review
- Microbiological Status of Venous Leg Ulcers and Its Predictors: A Single-Center Cross-Sectional Study.International journal of environmental research and public health · 2021Article
- Pleiotropic Effects of Statins: New Therapeutic Approaches to Chronic, Recurrent Infection byPharmaceutics · 2021Review
- Article
- Atorvastatin increases the production of proinflammatory cytokines and decreases the survival of Escherichia coli-infected mice.Scientific reports · 2019Article
- Statins improve the long-term prognosis in patients who have survived sepsis: A nationwide cohort study in Taiwan (STROBE complaint).Medicine · 2019Observational
- Statins: a viable candidate for host-directed therapy against infectious diseases.Nature reviews. Immunology · 2019Review
- Statin therapy in patients with community-acquired pneumonia.Clinical medicine (London, England) · 2017Observational
- Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.Current molecular pharmacology · 2017Article
- Is There Potential for Repurposing Statins as Novel Antimicrobials?Antimicrobial agents and chemotherapy · 2016Review
- Preoperative statin therapy and infectious complications in cardiac surgery.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2014Article
- Article
- Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus.Current pharmaceutical biotechnology · 2014Article
- Host cell invasion by Staphylococcus aureus stimulates the shedding of microvesicles.Biochemical and biophysical research communications · 2013Article
- Short term statin treatment improves survival and differentially regulates macrophage-mediated responses to Staphylococcus aureus.Current pharmaceutical biotechnology · 2013Article
- Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia.BMC microbiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Epidemiologic studies suggest that the incidence and severity of sepsis are ameliorated in patients on statins (3- hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) for cholesterol lowering indications. We sought to understand the mechanism underlying such protection and hypothesized that simvastatin would be protective in mice against acute infection with Staphylococcus aureus, the primary etiologic agent in sepsis. Mice were treated with simvastatin or buffer for two weeks and were subsequently challenged with S. aureus intratracheally or intravenously. Relative to buffer-treated mice, bacterial killing was enhanced 4-fold (p=0.02), systemic dissemination was reduced, and lethality was decreased (hazard ratio 8.8, 95% CI 2.5 to 31.3, p=0.001) in mice that were pretreated with simvastatin for two weeks. Systemic inflammatory response was abrogated and the local elaboration of inflammatory mediators was diminished. Serum concentrations of pro-fibrinolytic protein C were elevated (p=0.034), while the concentration of pro-coagulant tissue factor in bronchoalveolar lavage fluids was attenuated (reduced 25%), p=0.001, in simvastatin-treated mice. Taken together, these data indicate that extended treatment with simvastatin is protective during infection with S. aureus through enhanced bacterial clearance, anti-inflammatory, and anti-coagulant activities. These studies provide insights into the mechanism by which statins confer protection in acute infection, support the notion that statins may be effective adjuncts in the treatment of sepsis, and provide a rationale for randomized control trials in patients that are at a high risk for infection characterized by coagulopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.